Partnerships and collaborations are central to our goal of advancing innovative engineered natural killer (NK) cell therapies for the benefit cancer patients in need.
Our strategy is to work with global partners and academic centers of excellence to build on our understanding of the science of natural killer (NK) cells, expand our cell engineering capabilities and advance how engineered NK cell therapies are manufactured at scale as off-the-shelf therapies.
ONK Therapeutics is interested in forming additional partnership and collaborations, including the following areas:
with leading academic groups to promote understanding of the science of NK cells.
In-Licensing of technologies and IP to enhance our
engineered dual-targeted CAR-NK TRAILv platform
scaled up manufacturing of off-the-shelf NK cell therapies.
Out-Licensing of ONK Therapeutics technologies
to enhance partner NK cell therapy approaches.
Exploring potential combined therapeutic approaches
utilizing our cell therapy products with other anti-cancer therapies.
Partnerships and collaborations
with biopharmaceutical companies to bring optimized NK cell therapies to patients.
We have established partnerships with Academic Institutes, Manufacturing Companies as well as License Agreements with other partner companies.
If you are interested in partnering with ONK Therapeutics, please contact us.